Table 2.
Variable | Denosumab (n = 120) | ZA(n = 122) | P - value |
---|---|---|---|
Total incidence of SSEs | 10/120 | 21/122 | 0.04*a |
SSE incidence | |||
within 2 years | 3/120 | 4/122 | 0.21a |
after 2 years | 7/120 | 17/122 | 0.04*a |
* Statistically significant values. aAnalysed using the Chi-square test. ZA: zoledronic acid; SSEs: symptomatic skeletal events